KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.95

Patient-reported outcomes of a randomized phase III clinical trial of adjuvant radiation versus chemoradiation in intermediate risk, stage I/IIA cervical cancer patients treated with initial radical hysterectomy and pelvic lymphadenectomy (NRG/GOG-0263).

Dana M Chase, Helen Q Huang, Wei Deng, Wui-Jin Koh, William Rodgers, William Small, Kevin Albuquerque, Jyoti Mayadev, Charles A Leath, Bradley Monk, Beob-Jong Kim, Dae-Yeon Kim, Chi Heum Cho, Jae-Weon Kim, Jae Hong No, Laura Holman, Ashley Stuckey, Denise Fabian, Alexandra H Smick, Lari Wenzel, Karen Gil, Sang Young Ryu

Gynecol Oncol 202 102-109

PMID41056581
PMCIDPMC12767459
DOI10.1016/j.ygyno.2025.09.014
发表日期2025-10-07
入排依据:The study meets the criteria for being an original, randomized, Phase III trial of a drug-containing intervention (chemoradiation vs. radiation) in human oncology. However, it is excluded because the primary and only reported efficacy endpoints are patient-reported quality of life and symptom outcomes, which do not constitute a time-to-event efficacy endpoint as defined by the cohort criteria.
已检查 4 张 PubMed Figure,均未识别为 KM 图:Fig. 1.:CONSORT/入组流程图;Fig. 2.:CONSORT/入组流程图;Fig. 3.:CONSORT/入组流程图;Fig. 4.:AI 判定为 multi panel km。
摘要

摘要

OBJECTIVE: To prospectively evaluate the impact of adjuvant chemoradiation (RT + CIS) versus radiation (RT) on quality of life (QOL) and patient-reported outcomes (PROs) among patients with intermediate-risk, stage I-IIA cervical cancer treated with radical hysterectomy and pelvic lymphadenectomy. METHODS: Patients enrolled in GOG-0263 completed PRO/QOL assessments at baseline, 3, 7, and 36 weeks using the FACT-Cx Trial Outcome Index (FACT-Cx TOI), FACT/GOG-Neurotoxicity subscale (FACT/GOG-Ntx-4), the worst pain item from the Brief Pain Inventory (BPI), and five gastrointestinal/genitourinary (GI/GU) symptom items. Linear mixed models adjusted for baseline score, treatment, age, performance status, and country. RESULTS: Among 316 randomized eligible patients (RT + CIS: n = 158; RT: n = 158), questionnaire completion rates were 98 %, 90 %, 88 %, and 81 % at baseline, weeks 3, 7, and 36, respectively. Patients receiving RT + CIS reported a mean FACT-Cx TOI score 5.1 points lower than RT at 3 weeks (97.5 % CI: -8.6 to -1.6; p = 0.004) and 6.3 points lower at 7 weeks (97.5 % CI: -10.2 to -2.4; p = 0.002). By 36 weeks, scores had returned to baseline in both groups, with no significant difference (p = 0.386). Patient-reported neuropathy scores (FACT/GOG-Ntx-4) did not differ significantly between groups at any time point (p = 0.82). Patient-reported GI/GU symptoms and pain worsened at 3 weeks in both arms, followed by recovery to baseline by 36 weeks. CONCLUSION: QOL declined in both groups after treatment initiation, with greater short-term deterioration in the RT + CIS group. By 36 weeks, QOL and other PROs returned to baseline in both groups. Neuropathy, GI/GU symptoms, and pain showed no significant differences between treatment arms over time.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1.Fig. 1. Consort diagram of patients eligible for PRO/QOL analysis.
非 KM Figure
Fig. 2.Fig. 2.. The plot lines represent the FACT-Cx TOI scores. The estimated least-squares means (LSM) differences were obtained from a fitted mixed model adjusting for pre-treatment score (baseline score), patient’s age and performance status at the enrollment, and the country the treatment was administered. A larger score indicates favorable or better QOL. Note “**” indicates Hochberg adjusted p-value < 0.01.
非 KM Figure
Fig. 3.Fig. 3.. The plot lines represent the FACT/GOG-Ntx-4 scores. The estimated least-squares means (LSM) differences were obtained from a fitted mixed model adjusting for pre-treatment score (baseline score), patient’s age and performance status at the enrollment, and the country the treatment was administered. A larger score indicates less neurotoxic symptoms.
非 KM Figure
Fig. 4.Fig. 4.. The plot lines represent the patient-reported symptoms and pain scores. A larger score indicates better or favorable status except for the BPI worst pain score in which a larger score indicates worse pain.
非 KM Figure